What is targeted protein degradation (TPD)?
Targeted protein degradation (TPD) is an innovative therapeutic strategy that uses small molecules called protein degraders to selectively eliminate disease-causing proteins by hijacking the cell’s own disposal machinery — the ubiquitin-proteasome system (UPS). Unlike traditional inhibitors that block a protein’s function, TPD molecules physically remove the target protein from the cell entirely.
This approach is rapidly transforming drug discovery because it can address proteins previously considered ‘undruggable’ — those lacking a well-defined binding pocket or enzymatic activity. Explore Excelra’s GOSTAR™ TPD database — the most comprehensive protein degrader database for medicinal chemists and discovery teams.
What is a PROTAC? — PROTAC meaning explained
PROTAC meaning: PROTAC stands for PROteolysis TArgeting Chimera. A PROTAC is a bifunctional small molecule with three components:
- A warhead ligand that binds to the target protein of interest (POI)
- A chemical linker connecting both binding ends
- An E3 ligase ligand that recruits an E3 ubiquitin ligase to tag the target for degradation
Once the PROTAC bridges the target protein and E3 ligase, the ligase ubiquitinates the target. The tagged protein is then degraded by the proteasome. Critically, the PROTAC molecule is released intact and can initiate another degradation cycle — a key advantage of PROTAC drug discovery over conventional occupancy-based inhibitors.
TPD vs Traditional inhibition — Key differences
- Mode of action: Inhibitors block function; protein degraders eliminate the target protein entirely
- Undruggable targets: Targeted protein degradation addresses proteins without enzymatic activity or a defined binding pocket
- Catalytic activity: One PROTAC molecule degrades multiple copies of the target — substoichiometric dosing potential
- Resistance: TPD mechanisms may overcome resistance from target overexpression or point mutations in inhibitor binding sites
- Selectivity: PROTAC drug discovery selectivity is driven by both target and E3 ligase engagement, offering additional selectivity handles versus traditional inhibitors
Mechanism of action — How PROTAC drug discovery works
The targeted protein degradation cycle involves five key steps:
- The PROTAC simultaneously binds the target protein (POI) and recruits an E3 ubiquitin ligase
- The E3 ligase transfers ubiquitin molecules onto the target protein — polyubiquitination
- The polyubiquitin signal directs the target protein to the 26S proteasome
- The proteasome degrades the target protein into short peptide fragments
- The PROTAC molecule is released intact and initiates another degradation cycle
This catalytic, event-driven pharmacology is the defining feature of PROTAC drug discovery. Read Excelra’s blog: Scaffold Analysis for GOSTAR TPD for SAR-level insights into degrader design.
Molecular Glue Degraders — The Other TPD Modality
Molecular glue degraders are a related class of targeted protein degradation compounds. Unlike PROTACs, molecular glues are single small molecules — not bifunctional — that stabilize a protein-protein interaction between the target and an E3 ligase, leading to ubiquitination and degradation.
- PROTAC vs molecular glue — size: Molecular glues are significantly smaller, giving them better drug-like properties and oral bioavailability
- Molecular glues are harder to rationally design but are attracting enormous industry interest
- Thalidomide analogues (IMiDs like lenalidomide and pomalidomide) are the best-known molecular glue degraders
- Active area of AI-guided discovery and high-throughput screening
| Feature | PROTAC | Molecular Glue |
|---|---|---|
| Structure | Bifunctional | Single small molecule |
| Size | Larger | Smaller |
| Design Complexity | Higher | Moderate |
| Oral Bioavailability | Challenging | Better |
| Discovery Approach | Rational design | Often screening-driven |
Targeted protein degradation in drug discovery — Therapeutic areas
Targeted protein degradation is being actively explored across multiple disease areas where traditional inhibitors have failed or faced resistance:
TPD in oncology
The largest application area for targeted protein degradation. Protein degraders targeting BRD4, AR, ER, BCL-2, and KRAS are in clinical or advanced preclinical stages. Excelra’s cheminformatics services support scaffold analysis and structure-activity relationship (SAR)-driven optimization of oncology degraders.
TPD in neurodegenerative diseases
Tau and alpha-synuclein, implicated in Alzheimer’s and Parkinson’s disease, are being explored as targeted protein degradation targets. Their aggregated forms make conventional inhibition impractical, making protein degradation an attractive alternative strategy.
TPD in infectious diseases
Targeted protein degradation is being investigated to degrade viral proteins and bacterial targets, offering new strategies for antibiotic-resistant infections and emerging viral threats where standard inhibitors are insufficient.
Role of data and AI in protein degrader research
The complexity of PROTAC design — simultaneously optimizing two binding ends, linker chemistry, and ternary complex formation — makes data-driven and AI-assisted approaches essential in targeted protein degradation drug discovery:
- Structure-Activity Relationship (SAR) analysis of degrader datasets to identify optimal warheads, E3 ligase ligands, and linker chemistries
- AI/ML models predicting ternary complex formation, protein degradation efficiency, and DMPK properties
- Predictive modeling for proteome-wide selectivity profiling of protein degraders
- Large-scale PROTAC virtual library enumeration and computational screening
- Scientific data curation building high-quality, annotation-rich targeted protein degradation datasets from literature and patents
Excelra’s GOSTAR™ TPD — The protein degrader database
Excelra’s GOSTAR™ TPD database is the most comprehensive protein degrader database available, purpose-built for medicinal chemists, computational scientists, and drug discovery teams in the PROTAC drug discovery space.
- Curated PROTAC and molecular glue degrader data from peer-reviewed literature and patents
- E3 ligase, target protein, linker, warhead, and chemical structure annotations
- Protein degradation efficiency data: DC50, Dmax, cellular activity, and selectivity
- SAR-driven analysis tools for scaffold comparison and degrader optimization across chemical series
- Integration with GOSTAR™ small molecule data for cross-modality targeted protein degradation insights
Also explore GOSTAR™ Small Molecules and GOSTAR™ Large Molecules for Excelra’s complete medicinal chemistry intelligence portfolio.
Conclusion
Targeted protein degradation represents a paradigm shift in drug discovery — moving from blocking proteins to eliminating them. PROTACs, molecular glue degraders, and emerging protein degrader modalities are opening new target classes and offering hope for diseases resistant to conventional approaches. With tools like GOSTAR™ TPD — the leading protein degrader database — and Excelra’s cheminformatics and AI/ML services, research teams can accelerate degrader discovery with data-driven precision.
What is targeted protein degradation in simple terms?
Targeted protein degradation is a drug discovery approach that uses small molecules to destroy disease-causing proteins rather than simply blocking them. It works by tagging the target protein for destruction by the cell’s own waste disposal system — the proteasome — resulting in complete elimination of the problematic protein.
What does PROTAC mean and how does it work?
PROTAC meaning: PROteolysis TArgeting Chimera. A PROTAC is a bifunctional molecule that simultaneously binds a target protein and recruits an E3 ubiquitin ligase. The E3 ligase tags the target with ubiquitin, directing it to the proteasome for degradation. Because the PROTAC is released after each cycle, one molecule can degrade many copies of the target protein — a key advantage in PROTAC drug discovery.
What is the difference between a PROTAC and a molecular glue?
A PROTAC is a bifunctional molecule with two distinct binding ends connected by a linker. A molecular glue degrader is a single, smaller molecule that stabilizes an interaction between the target and an E3 ligase. Both achieve targeted protein degradation but differ significantly in design, size, and optimization strategy.
What diseases are targeted protein degradation approaches being developed for?
Targeted protein degradation is most advanced in oncology, with protein degraders targeting BRD4, AR, ER, BCL-2, and KRAS. It is also being explored for neurodegenerative diseases (tau, alpha-synuclein), immunological conditions, and infectious diseases where traditional inhibitors face limitations.
What data does the GOSTAR TPD protein degrader database contain?
The GOSTAR™ TPD database — Excelra’s protein degrader database — contains curated PROTAC and molecular glue data including target protein, E3 ligase, warhead, linker, protein degradation efficiency (DC50, Dmax), selectivity, and cellular activity, all sourced from peer-reviewed literature and patents.
How does AI support PROTAC drug discovery?
AI and machine learning in PROTAC drug discovery predict ternary complex formation, optimize linker length and chemistry, forecast ADMET properties, and screen virtual PROTAC libraries at scale — significantly reducing the iterative synthesis cycles required in conventional targeted protein degradation research.
